Fate Therapeutics Announces Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy
August 16 2017 - 8:00AM
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company
dedicated to the development of programmed cellular immunotherapies
for cancer and immune disorders, announced today that the U.S.
Patent and Trademark Office has issued U.S. Patent No. 9,675,641
covering the use of prostaglandins as viral transduction enhancers
for the genetic modification of CD34+ hematopoietic cells. The
patent, which expires in 2029, is owned by the Indiana University
Research and Technology Corporation and is licensed exclusively to
Fate Therapeutics in all fields.
“The use of small molecules in the manufacture of cell therapies
is proving to be a key component for promoting efficacy.
Studies have demonstrated that ex vivo small molecule
modulation can enhance the viral transduction, engraftment and
survival of CD34+ cells and the persistence, proliferation and
anti-tumor activity of NK cells and T cells,” said Scott Wolchko,
President and Chief Executive Officer of Fate Therapeutics. “Using
prostaglandins to improve vector copy number and percentage of
hematopoietic cells transduced in the manufacture of gene therapies
is a promising approach to help enable the development of curative
treatments for a range of severe genetic disorders.”
This newly-issued patent is the second issued U.S. patent in
this family. The Company’s proprietary rights broadly cover methods
of using prostaglandins and viral vectors, including lentiviral
vectors, to enhance ex vivo genetic engineering of hematopoietic
cells. The Company also has filed corresponding patent
applications to seek similar patent protection in key markets
throughout the world, including Europe and Japan.
Fate Therapeutics has an extensive intellectual property
portfolio covering ex vivo small molecule modulation of
hematopoietic cells. Multiple groups have shown that ex vivo small
molecule modulation, including modulation with prostaglandins in
particular, has the potential to significantly enhance the efficacy
of hematopoietic cell therapies.
About Fate Therapeutics, Inc. Fate Therapeutics
is a clinical-stage biopharmaceutical company dedicated to the
development of programmed cellular immunotherapies for cancer and
immune disorders. The Company's hematopoietic cell therapy pipeline
is comprised of NK- and T-cell immuno-oncology programs, including
off-the-shelf product candidates derived from engineered induced
pluripotent cell lines, and immuno-regulatory programs, including
product candidates to prevent life-threatening complications in
patients undergoing hematopoietic cell transplantation and to
promote immune tolerance in patients with autoimmune disease. Its
adoptive cell therapy programs are based on the Company's
novel ex vivo cell programming approach, which it applies
to modulate the therapeutic function and direct the fate of immune
cells. Fate Therapeutics is headquartered in San Diego, CA. For
more information, please visit www.fatetherapeutics.com.
Forward-Looking Statements This release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements regarding the scope and enforceability of the Company’s
intellectual property portfolio. These and any other
forward-looking statements in this release are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that any of
the patents in the Company’s intellectual property portfolio may be
challenged and that such a challenge may be successful, resulting
in loss of any such patent or loss or reduction in the scope of one
or more of the claims of a challenged patent. For a discussion of
other risks and uncertainties, and other important factors, any of
which could cause our actual results to differ from those contained
in the forward-looking statements, see the risks and uncertainties
detailed in the Company’s periodic filings with the Securities and
Exchange Commission, including but not limited to the Company’s
most recently filed periodic report, and from time to time the
Company’s other investor communications. Fate Therapeutics is
providing the information in this release as of this date and does
not undertake any obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or otherwise.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Sep 2023 to Sep 2024